ESPAC-1 trial progress report: The european randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 570-577

  Neoptolemos, J P ^a   Kerr, D J ^a   Beger, H ^b   Link, K ^b   Pederzoli, P ^c   Bassi, C ^c   Dervenis, C ^d   Fernandez Cruz, L ^e   Lacainet F ^f   Friess, H ^g   Biichler, M ^g  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF VERONA   (Italy)

^d AGIA OLGA HOSPITAL   (Greece)

^e HOSPITAL CLÍNIC   (Spain)

^f HÔPITAL TENON   (France)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

5 Fluorouracil; Chemotherapy; Folinic acid; Radiotherapy; Surgery

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EUROPE; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 9844264852     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201503     Document Type: Article

References (54)

1. Parkin DM, Muir CS, Whelan SL, Gao Y-T, Ferlay J, Powell J (eds): Cancer Incidence in Five Continents, vol VI, Lyon, International Agency for Research on Cancer, 1992, IARC Scientific Publ No, 120.
2. Fernandez E, Lavecchia C, Porta M, Negri M, Lucchini F, Levi F: Trends in pancreatic cancer mortality in Europe, 1955-89, Int J Cancer 1994:57:786-792.
3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP: Treatment and survival in 13.560 patients with pancreatic cancer, and incidence of the disease in the West Midlands: An epidemiological study, Br J Surg 1995;82:111-115.
4. Gudjonson B: Cancer of the pancreas, Fifty years of surgery, Cancer 1987:9:2284-2303.
5. Office of Population Censuses and Surveys: Mortality Statistics, Cause: Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales, Series DH2, No, 19, London, HMSO, 1992.
6. Carter DC: Cancer of the pancreas, Gut 1990: 31:494-496.
7. Cancer Registry of Norway: Survival of Cancer Patients, Cases Diagnosed in Norway 1968-75, Oslo, Cancer Registry of Norway, 1980.
8. Russell RCG: Surgical resection for cancer of the pancreas, Clin Gastroenterol 1990:4:889-916.
9. Beger HG, Link KH, Poch B, Gansauge F: Pancreatic cancer: Recent progress in diagnosis and treatment: in Neoptolemos JP, Lemoine NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Blackwell Science, 1996, pp 227-235.
10. Trede M, Schwall G, Saeger H-D: Survival after pancreatoduodenectomy, 188 resections without an operative mortality, Ann Surg 1990: 211:447-458.
11. Gall FP, Kessler N, Hermanek P: Surgical treatment of ductal pancreatic carcinoma, Eur J Surg Oncol 1991:17:173-181.
12. Kanvu F, Suzuki M, Imaizumi T: Whipple operation for pancreatic carcinoma: Japanese experience; in Beger HG, Biichlcr M, Malfer-thciner P (eds): Standards in Pancreatic Surgery, Berlin, Springer, 1993, pp 6467-6553.
13. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma, Am J Surg 1993;165:68-72.
14. Takahashi S, Ogata Y, Tsuzuki T: Combined resection of the pancreas and portal vein for pancreatic cancer, Br J Surg 1994:81:1190-1193.
15. Allcma JH, Reinders ME, Van Gulik TM, Koelcmay MJW, Ban Leeuwen DJ, De Wit LT, Gouma DJ, Obertop FI: Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region, Cancer 1995;75:2069-2076.
16. Nitecki SS, Sarr MG, Colby TV, Van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas, Is it really improving, Ann Surg 1995;221:59-66.
17. Yco CJ, Cameron JL, Allemoe KD, Sitzman JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas, 201 patients, Ann Surg 1995:221:721-733.
18. Neoptolemos JP, Russel] RCG, Bramhall S, Theis B for the UK Pancreatic Cancer Group: Low mortality following resection for pancreatic and periampullary tumours in 1.026 patients: UK survey of pancreatic specialist units, Br J Surg 1997, in press.
19. Lieberman MD, Kilbum H, Lindsey M, Brennan MF: Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy, Ann Surg 1995;222:638-645.
20. Wade TP, Halaby IA, Stapleton DR, Virgo KS, Johnson FT: Population based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals 1989-1994, Surgery 1996; 120:680-687.
21. Wagner M, Friess FI, Biichlcr MW: Conservative versus radical resections of the pancreas: in Neoptolemos JP, Lcmoine NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Blackwell, 1996, pp 248-270.
22. Pedrazzoli S, Di Carlo V, Dionigi R, Michclas-si F, Mosca F, Pedcrzoli P: Does extended lym-phadenectomv improve survival in the surgical treatment of pancreatic cancer? Results of a prospective trial (abstract), Digestion 1997: 58(suppl 2):19.
23. Neoptolemos J P, Bramhall S, Kerr DJ: Principles of adjuvant treatment in pancreatic cancer; in Beger H, Buchler M, Schoenberg M (eds): Cancer of the Pancreas, Universitats verlagUlm, 1966, pp 479-487.
24. Ishikawa D, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa FI, Intaoka S, Iwanaga T: Practical usefulness of lymphatic and connective tissue in the clearance for the carcinoma of the pancreas head, Ann Surg 1988:208:215-220.
25. Manabe T, Oshio G, Baba N, Miyashita T, Asano N, Tamura K, Yamaki K, Nonaka A, Tobc T: Radical pancreatectomy for ductal carcinoma of the head of the pancreas, Cancer 1989:64:1132-1137.
26. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Chamsangavcj C, Cleary KR, El-Naggar A, Fenoglio CJ, Lee JE, Evans DB: Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence, Ann Surg 1996:223:154-162.
27. Bramhall SR, Neoptolemos JP: Adjuvant treatment of pancreatic cancer: in Neoptolemos J P, Lemoinc NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Blackwell, 1996, pp 288-307.
28. Garton GR, Gunderson LL, Nagomey DM, Donohue JH, Martin JK, Mcllrath DC, Cha SS: High-dose preoperativc external beam and intraopcrativc irradiation for locally advanced pancreatic cancer, Int J Radiat Oncol Biol Phys 1993:27:1153-1157.
29. Hoffman JP, Wccsc JL, Solin LJ, Engstrom P, Agarwal P, Barber I.W, Guttman MC, Utwin S, Salazar FI, Eisenberg BL: A pilot study of pre-operative chcmoradiation for patients with localized adenocarcinoma of the pancreas, Am J Surg 1995:169:71-77.
30. lshikawa O, Ohigashi FI, Intaoka S, Sasaki Y, Iwanaga T, Matayoshi Y, Inoue T: Is the longterm survival rate improved by preoperativc irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head, Arch Surg 1994;129:1075-1080.
31. Staley CA, Lee JE, Cleary KR, Abbruzzcsc JL, Fenoglio CJ, Rich TA, Evans BD: Preoperativc chcmoradiation, pancreaticoduodenectomy and intraopcrativc radiation therapy for adenocarcinoma of the pancreatic head, Am J Surg 1996;171:118-125.
32. Spitz FR, Abbruzzese JL, Lee JF., Pisters PWT, Lowy AM, Fenoglio CJ, Clary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB: Prcoperative and post-operative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 1997:15:928-937.
33. Kaiser MH, Ellengerg SS: Pancreatic cancer, Adjuvant combined radiation and chemotherapy following curative resection, Arch Surg 1985:120:899-903.
34. Bakkcvold KE, Amesjo B, Dahl O, Kambestad B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vatcr, Results of a controlled, prospective, randomized multiccntre study, Eur J Cancer 1993:29:698-703.
35. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer, Cancer 1987:59: 2006-2010.
36. Gastrointestinal Tunior Study Group: Therapy of locally unrcscctable pancreatic carcinoma: A randomized comparison of high dose (6.000 rads) radiation alone, moderate dose radiation (4,000 rads) and high dose radiation and 5-fluorouracil, Cancer 1981:48:1705-1710.
37. United Kingdom Pancreatic Cancer Group (UKPACA): Adjuvant therapy following resection of pancreatic cancer (abstract), Gut 1993; 34:1290.
38. Arbuck SG: Chemotherapy for pancreatic cancer, Clin Gastroenterol 1990:4:953-968.
39. Cullinan S, Moertcl CG, Eieand HS, Schutt AJ, Krock JE, Foley JF, Norris BD, Kardinal CG, Tschetier LK, Barlow JF: A phase III trial on the therapy of advanced pancreatic carcinoma, Evaluation of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cispla-tin, Cancer 1990:65:2207-2212.
40. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC: Resection margins in carcinoma of the head of the pancreas, Implications for radiation therapy, Ann Surg 1993; 217:144-148.
41. Schulte M, Kent SE: The molecular genetics of pancreatic adenocarcinoma; in: Neoptolemos JP, Lemoine NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Black-well, 1996, pp 115-132.
42. Hertel LW, Boder GB, Kroin JS, Rinzcl SM, Poore GA, Todd CG, et al: Evaluation of the antitumor activity of gcmcitabinc, Cancer Res 1990:50:4417-4422.
43. Huang P, Chubb S, Hertel LW, Grindey G, Plunkett W: Action of gemcitabine on DNA synthesis, Cancer Res 1991:52:6110-6117.
44. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Madiano MR, Cripps MC, Portenoy RK, Stomiolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Vanhoff DD: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomised trial, J Clin Oncol 1997:15:2403-2413.
45. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, Green MR, Tarassoff PG, Brown TD, Casper EJ, Storniolo A-M, Von HoffDD: A phase II trial of gemcitabine in patients with 5-DU refractory pancreas cancer, Ann Oncol 1996:7:347-353.
46. Bramhall S, Stamp GHH, Lemoine NR, Neop-tolemos JP: The matrix metalloproteinases and their inhibitors in pancreatic cancer, in Ncop-tolcmos JP, Lemoine NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Blackwell, 1996, pp68-9l.
47. Bramhall SR, Stamp GWH, Dunn J, Lemoine NR, Neoptolcmos JP: Expression of collage-nase (MMP2), stromelvsin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease, Br J Cancer 1996:73:972-978.
48. Bramhall SR, Lemoine NR, Stamp GWH, Neoptolcmos JP: Imbalance of expression of matrix metalloproteinases and tissue inhibitors of the matrix metalloproteinases in human pancreatic cancer, J Pathol, in press.
49. Evans JD, Bramhall SR, Stark A, Hinley H, Porter C, Osborne L, Daniel F, Carmichael J, Intrie C, Johnson CD, Neoptolcmos JP: A phase II trial of Marimastat (BB-2516) in advanced pancreatic cancer (abstract), Int J Pan-crcatol 1996:19:218.
50. Link KH, Gansauge F, Pillasch J, Rilinger N, Buchler M, Beger HS: Regional treatment of advanced nonreseclablc of resected pancreatic cancer via eeliae axis perfunction, First results of a single institution study, Dig Surg 1994:11: 414-419.
51. Folkntan J: Angiogencsis in cancer, vascular, rheumatoid and other disease, Nat Med 1995: 1:27-31.
52. Gjcrtsen MK, Bakka A, Brcivik J, Saeterdal I, Gcddcdahl T, Stokkc KT, Solheim BG, Fgge TS, Soreide O, Thorsby E, Gaudemack G: Ex-vivo Ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study, Int J Cancer 1996:65:450-453.
53. Lcmoine NR: Strategies for genetic intervention in pancreatic cancer; in Neoptolcmos JP, Lemoine NR (eds): Pancreatic Cancer: Molecular and Clinical Advances, Oxford, Blackwell, 1996, pp 181-193.
54. Greer, NK, Youngs DJ, Neoptolcmos JP, Fricdlos F, Knof RJ, Springer CJ, Anzclark GM, Michael NP, Melton RG, Young LS, Kerr DJ, Searle PF: Sensitization of colorectal and pancreatic cancer lines to the prodrug 5-aziri-din-1 -yl-2.4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E, col' nitroreductase gene, Cancer Gene Thcr 1997;4:229-238.